Wealthfront Advisers LLC Has $6.26 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Wealthfront Advisers LLC reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 31.4% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 15,431 shares of the medical research company’s stock after selling 7,068 shares during the period. Wealthfront Advisers LLC’s holdings in Thermo Fisher Scientific were worth $6,257,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the company. Nuveen LLC acquired a new position in Thermo Fisher Scientific during the 1st quarter valued at about $532,360,000. EdgePoint Investment Group Inc. acquired a new position in Thermo Fisher Scientific in the first quarter valued at approximately $172,139,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in Thermo Fisher Scientific by 13.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,750,923 shares of the medical research company’s stock valued at $1,368,859,000 after acquiring an additional 329,974 shares during the last quarter. Auto Owners Insurance Co grew its holdings in Thermo Fisher Scientific by 6,773.5% during the 1st quarter. Auto Owners Insurance Co now owns 288,000 shares of the medical research company’s stock worth $143,309,000 after acquiring an additional 283,810 shares during the period. Finally, Alliancebernstein L.P. lifted its stake in shares of Thermo Fisher Scientific by 18.3% in the 1st quarter. Alliancebernstein L.P. now owns 1,766,067 shares of the medical research company’s stock valued at $878,795,000 after purchasing an additional 272,747 shares during the period. Institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In other news, CAO Joseph R. Holmes sold 385 shares of the firm’s stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total value of $189,662.55. Following the completion of the transaction, the chief accounting officer owned 2,319 shares in the company, valued at $1,142,408.97. This trade represents a 14.24% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $500.96, for a total value of $5,009,600.00. Following the sale, the chief executive officer owned 115,174 shares in the company, valued at $57,697,567.04. The trade was a 7.99% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,666 shares of company stock valued at $13,990,971. 0.33% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. Barclays upped their price objective on Thermo Fisher Scientific from $585.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. Royal Bank Of Canada set a $561.00 price objective on shares of Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. Scotiabank raised shares of Thermo Fisher Scientific from a “sector perform” rating to a “sector outperform” rating and set a $590.00 target price for the company in a research note on Friday, July 11th. Leerink Partners boosted their price target on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday. Nineteen equities research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $595.75.

Thermo Fisher Scientific Stock Performance

TMO opened at $564.49 on Tuesday. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.50 and a quick ratio of 1.11. The company has a market capitalization of $213.16 billion, a price-to-earnings ratio of 32.61, a P/E/G ratio of 3.35 and a beta of 0.77. The business’s 50-day moving average price is $505.57 and its two-hundred day moving average price is $454.34. Thermo Fisher Scientific Inc. has a 1 year low of $385.46 and a 1 year high of $610.97.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.50 by $0.29. Thermo Fisher Scientific had a return on equity of 16.97% and a net margin of 15.02%.The business had revenue of $11.12 billion for the quarter, compared to analyst estimates of $10.90 billion. During the same quarter last year, the firm earned $5.28 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. Equities analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.